Alector licenses AL050 to Genentech for $100M upfront and up to $1.17B in milestones
Alector granted Genentech exclusive worldwide rights to develop and commercialize its AL050 engineered GCase program. The agreement provides Alector with a $100 million upfront payment and potential milestone payments of up to $1.17 billion, plus tiered royalties. A separate non‑exclusive license was secured from Spur Therapeutics for $15 million and a revenue‑share on sublicense income. The deals monetize the AL050 asset and secure needed IP support.
Why it matters
The upfront cash and future milestone potential improve Alector’s balance sheet and give investors a near‑term liquidity boost, while the partnership may accelerate AL050’s development. The company’s filing states the transactions are intended to monetize a non‑core asset and advance the program.
Key facts
- 1Alector received a $100 million upfront payment from Genentech. tradingview.com
- 2The Genentech deal includes up to $1.17 billion in potential milestone payments and tiered royalties. tradingview.com
- 3Alector exercised an option with Spur Therapeutics for a non‑exclusive worldwide license, agreeing to pay $15 million plus a percentage of sublicense‑related income. tradingview.com
- 4The agreements were signed and became effective on September 30 2026. tradingview.com
- 5AL050 is an investigational therapy targeting neurodegenerative diseases, including Parkinson’s disease. rttnews.com
Summary written by AlphAI from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.